JB/CALL/BIONTECH ADR/120/0.025/20.12.24 Share Price

Warrant

BNZGJB

CH1276772659

Market Closed - Swiss Exchange 08:50:00 28/05/2024 pm IST
0.1 CHF -9.09% Intraday chart for JB/CALL/BIONTECH ADR/120/0.025/20.12.24
3 months-33.33%
6 months-62.96%
Date Price Change
28/24/28 0.1 -9.09%
24/24/24 0.11 -21.43%
23/24/23 0.14 +16.67%

Delayed Quote Swiss Exchange

Last update May 28, 2024 at 08:50 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying BIONTECH SE
Issuer Bank Julius Bär
BNZGJB
ISINCH1276772659
Date issued 28/06/2023
Strike 120 $
Maturity 20/12/2024 (206 Days)
Parity 40 : 1
Emission price 0.43 CHF
Emission volume N/A
Settlement règlement en espèces
Currency CHF

Technical Indicators

Highest since issue 0.67 CHF
Lowest since issue 0.07 CHF
Delta0.28x
Omega 6.194
Premium33.61x
Gearing22.27x
Moneyness 0.7745
Difference Strike 25.9 $
Difference Strike %+21.58%
Spread 0.01 CHF
Spread %10.00%
Theoretical value 0.0950
Implied Volatility 40.30 %
Total Loss Probability 81.36 %
Intrinsic value 0.000000
Present value 0.0950
Break even 124.17 CHF
Theta-0x
Vega0.01x
Rho0x

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
86.52 EUR
Average target price
104.7 EUR
Spread / Average Target
+21.01%
Consensus
  1. Stock Market
  2. Warrants
  3. BNZGJB Warrant